<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:oboInOwl="http://www.geneontology.org/formats/oboInOwl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:obo="http://purl.obolibrary.org/obo/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Tan et al. Molecular Cancer 2014, 13:13 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  RESEARCH                                                                                                                                      Open Access <br />  <br /> Bosutinib inhibits migration invasion ack1 kras mutant non-small cell lung cancer <br /> Daniel SW Tan1,2, Benjamin Haaland3,4, Jia Min Gan5, Su Chin Tham5,10, Indrajit Sinha6, Eng Huat Tan1, Kiat Hon Lim7, <br /> Angela Takano7, Sai Sakktee Krisna1,2, Minn Minn Myint Thu7, Hoe Peng Liew8, Axel Ullrich9, Wan-Teck Lim1,3,10 Boon Tin Chua5,10* <br />  <br />  <br />   Abstract <br />   advent effective targeted therapeutics led increasing emphasis precise biomarkers accurate patient <br />   stratification.  role ACK1, non-receptor tyrosine kinase abrogating migration invasion <br />   KRAS mutant lung adenocarcinoma. Bosutinib, inhibits ACK1 2.7 nM IC50, inhibit cell migration <br />   invasion viability panel non-small cell lung cancer (NSCLC) cell lines. Knockdown ACK1 abrogated <br />   bosutinib-induced inhibition cell migration invasion specifically KRAS mutant cells. finding   confirmed vivo zebrafish metastatic model. Tissue microarray data 210 Singaporean lung adenocarcinomas <br />   indicate cytoplasmic ACK1 significantly expressed relative paired adjacent non-tumor tissue. Interestingly, <br />   ACK1 expression &#226;&#8364;&#339;normal&#226;&#8364;? tissue adjacent tumour, tumour, independently associated poor overall <br />   relapse-free survival. conclusion, inhibition ACK1 bosutinib attenuates migration invasion   context KRAS mutant NSCLC fulfil therapeutic niche combinatorial treatment approaches. <br />   Keywords: Lung cancer, ACK1, KRAS, Bosutinib, Metastasis <br />  <br />  <br /> Introduction                                                                        domains CRIB Cdc42 binds [4]. Lung cancer leading cause cancer related death                            C-terminal half protein interacts partners <br /> world-wide [1]. estimated ~228 190 new                          including clathrin, EGFR, ubiquitin, Nedd4 E3 ligase lung cancer cases ~159 480 lung cancer deaths                                Grb2 [5-8]. Recent work Mahajan et al. shows United States 2012 (http://seer.cancer.gov/statfacts/                        ACK1 phosphorylates AKT Tyr 176, resulting html/lungb.html). increasing number gen-                             activation [9]. reports implicated ACK1 <br /> etic alterations non-small cell lung cancer (NSCLC)                              expression amplification tumorigenesis amenable targeted therapeutics [2],                               different tissue types e.g. gastric, pancreatic lung <br /> emerging challenge identification factors                              [10,11]. High expression phosphorylated ACK1 cor- modulate attenuate intracellular signaling                             relates disease progression breast, prostate cascades implicated drug response resistance&#226;&#8364;                               pancreatic cancers [12-14], specific interactions enable better patient selection rational drug                             ACK1 kinase key signaling nodes e.g. <br /> combinations [3].                                                                   <span id='am-42' about='obo:IMR_0100035' typeof='owl:Thing obo:IMR_0100033 obo:IMR_0000947 obo:IMR_0000965 obo:IMR_0000966 obo:IMR_0000001'><span id='am-43' property="oboInOwl:hasDbXref" content="KEGG:C00280" datatype="xsd:string"></span><span id='am-44' property="rdfs:label" content="androgen" datatype="xsd:string"></span><span id='am-45' property="oboInOwl:hasDbXref" content="KEGG:C00523" datatype="xsd:string"></span><span id='am-46' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-47' property="oboInOwl:id" content="IMR:0100035" datatype="xsd:string"></span><span id='am-48' property="oboInOwl:hasDbXref" content="KEGG:C00535" datatype="xsd:string"></span>androgen</span> receptors prostate cancer. melanoma <br />   Activated Cdc42 associated kinase (ACK1) non-                                cell lines, ACK1 activated response integrin sig- <br /> receptor tyrosine kinase residing cytoplasm.                             naling, resulting cell spreading [15]. vivo, ACK1 <br /> kinase domain located N-terminal half                              expressing cells resulted aggressive metastatic <br /> protein followed multiple protein-protein interaction                            tumors [10,12] vitro silencing ACK1 gene <br />                                                                                     RAS-transformed NIH3T3 cells increased apoptosis <br />                                                                                     [16]. Recently, shown silencing ACK1 <br /> * Correspondence: btchua@imcb star.edu.sg <br /> 5 <br />  Singapore OncoGenome Laboratory, Institute Medical Biology, Agency                                                                                     results reduced ERK AKT phosphorylation Science Technology Research, Singapore, Singapore                               interestingly, EMT reversion [17]. <br /> 10 <br />   INM-SOG, Institute Molecular Cell Biology, Agency Science                 hypothesized ACK1 hyperactivity Technology Research, Singapore, Singapore list author information available end article <br />                                                                                     expression influences metastatic potential lung <br />  <br />                                       &#194;&#169; 2014 Tan et al.; licensee BioMed Central  Open Access article distributed terms Creative <br />                                       Commons Attribution License (http://creativecommons.org/licenses 2.0), permits unrestricted use, distribution,                                       reproduction medium, provided original work properly cited. Creative Commons Public Domain Dedication <br />                                       waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies data available article, unless                                       stated. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                           Page 2 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> adenocarcinoma targeted kinase inhibitors.       Bosutinib inhibition cell migration invasion Bosutinib (SKI-606) generation dual SRC-ABL           ACK1 dependent SRC-independent <br /> kinase inhibitor developed Wyeth (Pfizer) binds     SRC ACK1 play role cell motility prevents auto-phosphorylation ACK1 IC50             [17,21-24] bosutinib inhibit kinases, 2.7 nM [18,19]. results bosutinib inhibited        evaluated target kinases (ACK1 <br /> cancer cell migration invasion ACK-1 KRAS           SRC) mediating migratory effect. Using <br /> dependent manner &#226;&#8364;&#8220; vitro cell lines        NCI-H1792, KRAS mutated NSCLC cell, silenced vivo zebrafish model.  validated ACK1           ACK1 SRC measured migration <br /> protein expression 210 lung adenocarcinoma tissue             invasion bosutinib treatment. Real time PCR <br /> microarrays using immunohistochemistry, high               data (Figure 3A) showed silencing ACK1, SRC expression tumor ACK1 observed compared                effectively reduced respective transcript levels. paired adjacent &#226;&#8364;&#339;normal&#226;&#8364;? lung tissue. tumor          Expectedly, ACK1 SRC knockdown, cell migration <br /> ACK1 expression associated survival             invasion reduced ~50%, consolidating comes resected NSCLC, intriguingly, ACK1 expression           role kinases cell motility (Figure 3B <span id='am-11' about='obo:IMR_0200083' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0001349 obo:IMR_0000001 obo:IMR_0001698'><span id='am-12' property="rdfs:label" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-13' property="oboInOwl:id" content="IMR:0200083" datatype="xsd:string"></span><span id='am-14' property="oboInOwl:hasDbXref" content="KEGG:C00020" datatype="xsd:string"></span><span id='am-15' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-16' property="oboInOwl:hasExactSynonym" content="Adenosine 5&apos;-monophosphate" datatype="xsd:string"></span><span id='am-17' property="rdfs:label" content="AMP" datatype="xsd:string"></span>amp</span>; C). adjacent &#226;&#8364;&#339;normal&#226;&#8364;? lung associated worse              SRC-silenced cells, dose-dependent inhibition cell mi- <br /> overall relapse-free survival univariate         gration invasion observed treatment <br /> multivariate models.                                             increasing concentration bosutinib. contrast, <br />                                                                  ACK1 ACK1/SRC dual-silenced cells, bosutinib- <br />                                                                  induced inhibition cell migration abolished. Results <br />                                                                  effect observed second KRAS mutant <br /> Bosutinib inhibits KRAS mutant KRAS wild type <br />                                                                  NSCLC cell line, SK-Lu-1 (Additional file 1: Figure S1) <br /> cell migration invasion <br />                                                                  treated bosutinib. data support role previously demonstrated ACK1 plays                                                                  ACK1 target bosutinib inhibiting cell migration <br /> important role cell migration epithelial mesenych- <br />                                                                  invasion KRAS mutant cell lines. <br /> mal transition vitro expression gene <br /> silencing systems [17]. tested effect bosutinib <br />                                                                  Reduction lung cancer cell metastasis zebrafish cell migration panel NSCLC cell lines                                                                  embryos bosutinib ACK1 dependent <br /> migrate efficiently 8 &#206;&#188;m transwell 10% FBS <br />                                                                   examined vitro migratory invasive chemoattractant. tested invasive potential <br />                                                                  inhibition bosutinib translated metastasis cell lines using Matrigel&#226;&#8222;&#162; assay. shown Figure 1, <br />                                                                  inhibition vivo. Zebrafish recognized model sub-lethal concentration (0.1, 0.5 1 &#206;&#188;M) bosutinib <br />                                                                  human malignancy conserved genetics cell sufficient inhibit cell migration invasion                                                                  biology [25]. Using zebrafish host organism, dose-dependent manner. Unexpectedly, ob- <br />                                                                  developed quantitative vivo cell migration assay <br /> served KRAS mutant cells shown Figure 1A                                                                  monitor response cells anti-cancer agents. <br /> C. contrast, bosutinib effect migration 3 <br />                                                                  Transparency embryos provides unique 4 KRAS wild type NSCLC cell lines (Figure 1B).                                                                  ability visualize vivo drug responses migratory <br /> addition, 4 KRAS mutant cell lines showed reduced <br />                                                                  changes cancer cells real time. injected <br /> migration invasion Matrigel assay, KRAS <br />                                                                  boluses fluorescently labeled human NCI-H2009 cells, <br /> WT cell lines tested inhibited bosutinib <br />                                                                  successfully transfected siRNA (Figure 1D). <br />                                                                  ACK1, SRC negative control (Additional file 2: Figure <br />                                                                  S2), yolk sac 24&#226;&#8364;&#8220;30 h old embryos. labeled <br /> Effect bosutinib viability NSCLC cell lines          NCI-H2009 cells observed migrate independent KRAS status                                       injection site metastasized various parts em- panel NSCLC lines, bosutinib reduced cell          bryos (Figure 4A). test effect bosutinib viability micromolar IC50 1&#226;&#8364;&#8220;5 &#206;&#188;M (Figure 2A        metastatic cells vivo, pretreated labeled cells B) apoptosis (Figure 2C) tested KRAS              bosutinib injecting embryos. <br /> mutant KRAS wild type (WT) lung cancer cell lines.           metastatic potential NCI-H2009 cells transfected <br /> Based steady state (D15) dosing bosutinib [MW              control SRC siRNA significantly reduced 530.44616] clinic 400 500 mg daily, Cmax           pretreatment low dose bosutinib (Figure 4A B) 190 ng/mL 273 ng/mL respectively, [20] ap-               significant reduction observed proximately corresponding vitro concentrations             cells transfected ACK1 siRNA (Figure 4C). 0.3 &#226;&#8364;&#8220; 0.5 &#206;&#188;M.  clinically relevant doses bosuti-      observations support role ACK1 target <br /> nib able inhibit migration invasion           bosutinib inhibiting cell migration invasion viability NSCLC cell lines.                                   KRAS mutant cell lines vivo. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                              Page 3 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  Figure 1 Bosutinib inhibit KRAS mutant cell migration invasion KRAS wildtype cells. serum-starved KRAS  &amp; C) mutant <br />  (B &amp; D) wildtype cells trypsinized seeded upper chamber Transwell (8 mm pore, &amp; B) Matrigel&#226;&#8222;&#162; (C &amp; D),  presence DMSO bosutinib various concentrations (0.1, 0.5 1 &#206;&#188;M). Medium containing 10% FBS DMSO bosutinib (0.1, 0.5  1 &#206;&#188;M) used chemoattractant lower chamber. migrated invaded cells fixed stained 0.5% crystal violet blue  6 h 24 h respectively. Cells migrated invaded filter counted. Experiments carried duplicates  random fields counted. percentage migrated invaded cells expressed respect DMSO treated cells. <br />  <br />  <br /> ACK1 highly expressed lung adenocarcinoma                            paired surrounding non-tumor &#226;&#8364;&#339;normal&#226;&#8364;? tissue  2005, Van der Horst et al. [10] showed ACK1                    dependently associated worse overall relapse-free <br /> gene amplified numerous cancer types including lung                  survival, shown Table 1. <br /> cancers correlated metastatic potential poor prognosis.  validated total protein ex-                   Discussion <br /> pression ACK1 using immunohistochemistry staining                       era molecularly-directed therapeutics NSCLC, 210 lung adenocarcinoma house tissue                           increasing discovery novel <br /> microarray (TMA). comparison surrounding paired                    biomarkers improved patient stratification treat- <br /> non-tumor lung sections, ACK1 substantially signifi-                ment. EGFR mutant ALK translocated NSCLC <br /> cantly  p &lt; 0.001) expressed tumor tissue               successfully targeted clinic, KRAS muta- <br /> immunohistochemisty summaries (including ACK1 max-                         tions account 15-22% cases <span id='am-5' about='oboInOwl:date' typeof='owl:Thing'>date</span>, imum staining intensity, percentage staining, IP).                 clinically validated targeted therapies [2,26]. article, <br /> difference IP score  Immunohistochemistry section                   present novel data highlighting potential therapeutic Method <span id='am-23' about='obo:IAO_0000115' typeof='owl:Thing'>definition</span>) tumour adjacent                      role bosutinib abrogating migration invasion non-tumour lung tissue illustrated Figure 5.                         KRAS mutant NSCLC cell lines ACK1. <br />                                                                               unexpected observation bosutinib-mediated  <br /> ACK1 expression adjacent &#226;&#8364;&#339;normal&#226;&#8364;? lung tissue                      tenuation migration invasion specifically KRAS <br /> portends poorer outcomes lung adenocarcinoma                            mutant cell lines underscores importance evaluating ACK1 IHC data subjected statistical analysis.                   targeted therapeutics appropriate genetic context.  significant univariates predicted                  experiments reveal potential identifying <br /> overall relapse-free survival stage, grade, smoking               therapeutic niches oncogenic drivers, &#226;&#8364;&#339;off- <br /> status, histology, non-tumor ACK1 expression,                       target&#226;&#8364;? inhibition selected kinases confer desirable <br /> shown supplementary data, Additional file 3: Table S1.                  anti-cancer effects reducing cell viability Multivariate models developed, adjusting                      induction apoptosis.  induction apoptosis <br /> relationship prognosis important clinical                  bosutinib doses 1 &#206;&#188;M likely involves non- <br /> covariates stage grade, context Cox propor-                specific multi-kinase inhibition. contrast, inhibition tional hazards model. Interestingly, ACK1 expression                  migration invasion observed doses low  Tan et al. Molecular Cancer 2014, 13:13                                                                                                     Page 4 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  Figure 2 Effect bosutinib viability NSCLC cell lines independent KRAS status. KRAS mutant   wildtype (B) NSCLC  Normal Human Bronchial Epithelial (NHBE) cells seeded 96 plates 24 h. cells treated various concentrations <br />  (0&#226;&#8364;&#8220;10 &#206;&#188;M) bosutinib 72 h followed cell viability assay measured CellTitre Glo. cell viability results normalized DMSO-treated <br />  controls expressed percentage. (C) NSCLC cells treated bosutinib 72 h different concentrations. Caspase3/7 activities  measured using Caspase-Glo 3/7 luminescent assay kit. enzymatic activity expressed value respect untreated cells. <br />  <br />  <br />  <br /> 0.1 &#206;&#188;M, consistent bosutinib-specific &#226;&#8364;&#339;on-target&#226;&#8364;?                           Separately, assembly 210 tumors, kinase inhibition clinically relevant doses (Cmax                        created TMAs examine clinical relevance ACK1 <br /> bosutinib 400 mg daily 190 ng/mL approxi-                       expression NSCLC. chose focus total <br /> mately 0.3 &#206;&#188;M).                                                                ACK1 expression phospho-ACK1 reasons. <br />   study, silencing ACK1 SRC signifi-                        shown previously cell lines  <br /> cantly reduced cell migration invasion, confirming                   expression wild type ACK1 plasmid resulted ACK1 <br /> role regulating metastasis. addition, using bosutinib                    phosphorylated active [17]. Secondly, com- dose 0.5 &#206;&#188;M 1 &#206;&#188;M)) <span id='am-1' about='obo:IMR_0000947' typeof='owl:Thing obo:IMR_0000001'><span id='am-2' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-3' property="oboInOwl:id" content="IMR:0000947" datatype="xsd:string"></span><span id='am-4' property="rdfs:label" content="chemical" datatype="xsd:string"></span>chemical</span> probe,                           mercial available phospho-ACK1 antibody optimized <br /> observed effect migration invasion                        TMAs, artefactual dephosphorylation abrogated knockdown ACK1 SRC,                               inconsistencies time fixation paraffin embedded <br /> highlighting importance ACK1 signaling axis.                     surgical samples limit accuracy depicting intrin- supported zebrafish model,                        sic signaling activity [28,29]. cohort 210 patients <br /> siRNA ACK1 abrogated anti-migratory effect                           lung adenocarcinoma, substantial bosutinib. previously reported interacting partner                     significant difference ACK1 protein expression ACK1, AXL shown regulate cell migration                         non-tumor tumor cores, consistent role invasion breast cancer. NSCLC panel,                          tumorigenesis.  did clear inverse absence AXL NCI-H1792 effect                           association tumor ACK1 expression bosutinib-induced inhibition cell migration                          survival, suggesting nuanced relationship clinical <br /> invasion (Additional file 4: Figure S3), suggesting                       outcomes. possible majority tumours contradistinct breast cancer [27]. AXL play                       TMA stage  ACK1 expression dominant role metastatic phenotype NSCLC.                            impact clinical outcome. later stage tumours, given <br /> Furthermore, given ACK1 activated                            central role ACK1 migration invasion, ceptor tyrosine kinases EGFR ALK [5,24],                           increase protein expression, regardless extent, bosutinib broader therapeutic relevance                            deleterious &#226;&#8364;&#8220; mitigating correlation NSCLC.                                                                         intensity percentage patient outcomes. Intriguingly, <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                     Page 5 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />                                                                            expression ACK1 paired surrounding adjacent <br />                                                                            &#226;&#8364;&#339;normal&#226;&#8364;? lung tissue associated poor outcome, <br />                                                                            suggesting ACK1 activation early event <br />                                                                            lung cancer carcinogenesis. <br />                                                                               interesting observation arising study                                                                            relationship KRAS, ACK1 cell migration, <br />                                                                            invasion EMT. date, direct connection <br />                                                                            proteins, exception publication <br />                                                                            Nur et al. [16]. work suggested ACK1                                                                            important pro-oncogenic factor downstream constitu- <br />                                                                            tive active RAS, probably mediating EMT. Consistent <br />                                                                            notion, numerous reports suggested                                                                            RAS activation TGF signaling results upregulation <br />                                                                            2 transcription factors, snail snug, repress <br />                                                                            E-cadherin induce EMT [30-32]. preliminary <br />                                                                            analysis twist, mesenchymal transcription factor using <br />                                                                            real time PCR panel NSCLC lines showed differ- <br />                                                                            ential high low twist mRNA RAS mutant WT <br />                                                                            cell lines respectively (data shown). panel                                                                            cell lines, preliminary data suggests RAS-driven EMT <br />                                                                            migratory signals mediated ACK1. <br />                                                                               Recently, phase study bosutinib, including                                                                            expansion cohort colon, lung pancreatic cancer, <br />                                                                            reported [20]. objective tumor responses <br />                                                                            recorded trial did meet predetermined <br />                                                                            efficacy endpoints, stable disease observed 47%                                                                            NSCLC patients (n = 19), 16% patients dur- <br />                                                                            able disease control 24 weeks. Regrettably, <br />                                                                            KRAS EGFR status reported study, <br />                                                                            plausible high ACK1 expression stratify <br />                                                                            subgroup EGFR KRAS mutant patients likely                                                                            respond bosutinib. <br />                                                                               conclusion, ACK1 inhibition affects cell motility                                                                            migration particularly context KRAS mutant <br />                                                                            NSCLC cell lines, highly expressed lung adeno- <br />                                                                            carcinoma compared paired surrounding non-tumor <br />                                                                            tissue. Given implicated role ACK-1 EGFR, KRAS <br />                                                                            ALK signaling, suggest potential therapeutic <br />                                                                            niche combination studies bosutinib selecting                                                                            patients ACK-1 overexpression, specifically circum- <br />  Figure 3 Bosutinib inhibit cell migration invasion ACK1            venting tumor metastasis recurrence. <br />  dependent SRC- independent. NCI-H1792 transfected  siRNA (control, ACK1 SRC) using Oligofectamine 72 h. cells     Materials methods <br />  harvested 72 h.   Quantitative real-time PCR analysis                                                                            Lung cancer cell lines <br />  performed using 20 ng cDNA respective primers set ack1  src normalized gapdh. serum-starved cells trypsinized     Human lung adenocarcinoma cell lines [NCI-H1650, NCI- <br />  seeded upper chamber Transwell (8 mm pore, B)            H1792, NCI-H1838, NCI-H1975, NCI-H2009, NCI-H2291, <br />  Matrigel&#226;&#8222;&#162; (C), presence DMSO bosutinib various            NCI-H2444, HCC-95, HCC-193, EKVX SK-Lu-1]  concentrations (0.5 1 &#206;&#188;M). Medium containing 10% FBS DMSO         provided Max Planck Institute Biochemistry au- <br />  bosutinib (0.5 1 &#206;&#188;M) used chemoattractant lower <br />  chamber. cells fixed stained 0.5% crystal violet blue <br />                                                                            thenticated using STR profiling John Hopkins Fragment <br />  6 h (migration, B) 24 h (invasion, C). Cells migrated   Analysis Facility (April 2013). cells maintained  invaded filter counted. Experiments carried      Roswell Park Memorial Institute medium supplemented <br />  duplicates random fields counted.                            <span id='am-24' about='obo:IMR_0200448' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0001695 obo:IMR_0000001'><span id='am-25' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-26' property="oboInOwl:id" content="IMR:0200448" datatype="xsd:string"></span><span id='am-27' property="rdfs:label" content="L-Glutamine" datatype="xsd:string"></span><span id='am-28' property="oboInOwl:hasDbXref" content="KEGG:C00064" datatype="xsd:string"></span>L-glutamine</span> 10% fetal bovine serum,                                                                            SK-Lu-1 cells maintained Minimum Essen- <br />                                                                            tial Medium L-glutamine 10% fetal bovine serum. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                                    Page 6 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />  Figure 4 Reduction lung cancer cell metastasis zebrafish embryos bosutinib ACK1 dependent. Embryo injected Vibrant DiD <br />  labeled NCI-H2009 cells showing tumor foci burden determined segmented red channel (upper) scatter plot representation cell <br />  dissemination  . data series represents fish number injected embryos 3 biological replicates indicated (n). Comparative <br />  inhibition cell migration, measured Migration Index, untreated drug pretreated cells represented bar graph (right), <br />  Mean &#194;&#177; SD.   Embryos injected NCI-H2009 transfected control siRNA. (B) Embryos injected NCI-H2009 transfected SRC <br />  siRNA. (C) Embryos injected NCI-H2009 transfected ACK1 siRNA. <br />  <br />  <br />  <br /> Normal Human Bronchial Epithelial Cells (NHBE)                           fluoride, 0.2 &#206;&#188;g/ml Aprotinin) 20 minutes 4&#194;&#176;C, purchased Lonza (Basel, Switzerland), cultured                       protein concentration measured using BCA protein serum-free medium described Clonetics. cells                     assay (Thermo Scientific, Rockford, . Protein samples incubated 37&#194;&#176;C incubator 5% <span id='am-18' about='obo:IMR_0200324' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-19' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-20' property="rdfs:label" content="CO2" datatype="xsd:string"></span><span id='am-21' property="oboInOwl:hasDbXref" content="KEGG:C00011" datatype="xsd:string"></span><span id='am-22' property="oboInOwl:id" content="IMR:0200324" datatype="xsd:string"></span>CO2</span>.                               subjected SDS-PAGE transferred polyvi- <br />                                                                               nylidene difluoride membrane. Membranes blocked <br /> Reagents                                                                      5% milk PBST/TBST (0.1% Tween-20) incu- <br /> Bosutinib (SKI-606) purchased LC Laboratories                        bated primary antibodies: anti-ACK1  11) <br /> (Woburn, MA) prepared DMSO 10 mM stock.                             antibodies (Santa Cruz Biotechnology, Santa Cruz, CA), anti- compound diluted desired concentration                          &#206;&#178;-actin-HRP, anti-GAPDH-HRP, anti-SRC antibodies <br /> culture medium  DMSO) treatment. Results                            (Cell Signaling Technology&#194;&#174;, Beverly, MA). secondary separately validated bosutinib, synthesized                      antibodies anti-mouse anti-rabbit horseradish <br /> Vichem Chemie Research (Budapest, Hungary)                                peroxidase conjugated antibodies (GE Healthcare). Detec- <br />                                                                               tion performed using Immobilon Western Chemilu- <br /> Protein extraction Western blot analysis                                  minescence HRP substrate (Millipore, Billerica, MA). <br /> Cells lysed lysis buffer (50 mM HEPES, 150 mM <br /> NaCl, 1 mM EDTA, 10% Glycerin, 1% Triton X-100,                               Cell viability assay <br /> 10 mM Sodium <span id='am-6' about='obo:IMR_0200280' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-7' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-8' property="oboInOwl:id" content="IMR:0200280" datatype="xsd:string"></span><span id='am-9' property="oboInOwl:hasDbXref" content="KEGG:C00013" datatype="xsd:string"></span><span id='am-10' property="rdfs:label" content="Pyrophosphate" datatype="xsd:string"></span>pyrophosphate</span>, 10 mM sodium fluoride,                            Cancer cell lines NHBE cells seeded 96 2 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl                         plates 80% confluency (1000 5000 cells). Cells  Tan et al. Molecular Cancer 2014, 13:13                                                                                                      Page 7 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br />     Figure 5 ACK1 highly expressed lung adenocarcinoma. Immunohistochemistry staining performed 210 NSCLC tumor paired <br />     non-tumor sections house TMA using anti-ACK1 (C20, material method).   ACK1 immuno-positivity defined presence <br />     brown cytoplasmic staining. Staining intensity scored 0, 1+, 2+ 3+   weak, moderate strong staining, respectively). (B) <br />     Percentage positively stained tumor cells assessed proportion total number tumor cells present section. Intensity percentage <br />     score, IP, defined product maximum immunostaining intensity percentage tumor cells stained. <br />  <br />  <br /> treated various concentrations Bosutinib 72 h.                       8.0 &#206;&#188;m pore polycarbonate membrane insert <br /> Cell viability measured using CellTiter-Glo reagent                          (Corning, , Corning, NY), duplicates. Cell migrated <br /> (Promega, Madison, WI) according manufacturer&#226;&#8364;&#8482;s                               lower chamber containing 600 &#206;&#188;L medium <br /> instructions. Cell viability results normalized                          10% FBS DMSO Bosutinib (0.1, 0.5 DMSO-treated controls expressed percentage.                               1 &#206;&#188;M) 6 h. followed fixation staining                                                                                  0.5% crystal violet blue 25% methanol. Non-migrating <br /> Apoptotic assay                                                                  cells removed cotton swab migrated cells <br /> Cells seeded 96 plates 80% confluency                          counted random microscopic fields. Invasion <br /> overnight (1000&#226;&#8364;&#8220;5000 cells) treated Bosutinib                        assay performed migration assay replacing <br /> various concentrations 72 h. Apoptosis measured                          transwell Matrigel&#226;&#8222;&#162; transwells (Corning, , <br /> using Caspase-Glo&#194;&#174; 3/7 luminescent assay according                            Corning, NY). <br /> manufacturer&#226;&#8364;&#8482;s instructions (Promega Corp., Madison, WI). <br /> Caspase activity expressed percentage DMSO                           siRNA silencing <br /> treated cells set 100%.                                                       Cells seeded 24 plate transfected <br />                                                                                  siRNA ACK1 (#103419), SRC (#683), nega- <br /> Migration invasion assay                                                     tive control (Ambion, Austin, TX) using Oligofectatmine&#226;&#8222;&#162; <br /> Serum-starved cells (50000 100000) suspended                          transfection reagent (Invitrogen, Carlsbad, CA) described <br /> 200 &#206;&#188;L serum-free medium treated Bosutinib                           manufacturer&#226;&#8364;&#8482;s protocol. Cells collected use (0.1, 0.5 1 &#206;&#188;M) DMSO control. Cells loaded                           72 h transfection. <br /> Table 1 Unique relationship* overall relapse-free survival ACK1 IP tumor non-tumor tissues <br />                                      Overall survival                                                 Relapse-free survival <br /> Tumor ACK 1 IP                       p = 0.982 (overall)  10 units) 0.999 (0.930-1.074)           p = 0.719 (overall)  10 units) 0.987 (0.916-1.062) <br /> Non-tumor ACK 1 IP                   p &lt; 0.001 (overall)  10 units) 2.002 (1.370-2.927)           p &lt; 0.001 (overall)  10 units) 1.907 (1.328-2.737) <br /> * <br /> Adjusted stage grade. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                           Page 8 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> Quantitative Real-Time PCR                                       drug treatment imaged using confocal fluorescence <br /> Total RNA extracted purified using RNeasy                microscope (Olympus, FV1200). Multiple plane images <br /> Mini Kit (Qiagen, Germantown, MD). Superscript&#226;&#8222;&#162; III              taken embryo composite images strand synthesis kit ((Invitrogen, Carlsbad, CA)           using ImageJ software. composite images gathered, used reverse transcription manufacturer&#226;&#8364;&#8482;s          aligned specific orientation, analyzed scatter <br /> recommended conditions. Real-time PCR cDNA              plot determine tumor foci position relative injection <br /> product performed Applied Biosystems&#226;&#8364;&#8482;s 7500             site (0,0 graph). Number metastatic tumor cell foci <br /> Fast real-time PCR (Foster City, CA). Primers             positions calculated applying minimum area filter <br /> specific ACK1, SRC GAPDH used               exclude unanchored migrating single cells. Axes rep- Fast SYBR&#194;&#174; green master mix (Applied Biosystems,            resent distance (&#206;&#188;m) injection site. Cumu- <br /> Foster City, CA) PCR amplification manufac-            lative distance (CD) traveled metastatic tumor cell foci <br /> turer&#226;&#8364;&#8482;s conditions.                                               &#206;&#188;m) calculated graph                                                                  sum distances identified tumor foci Zebrafish metastasis model                                       injection point single embryo. zebrafish metastasis model (Zgraft) developed          Migration Index = 1/n &#226;&#710;&#8216;(CD 48 h/Total number approved protocols Wayne State University          viable cells 48 h) n number embryos <br /> Institutional Animal Care Use Committee (USA)                considered experiment. University Windsor Animal Care Committee,                quantify surviving tumor cells zebrafish larvae, <br /> Canadian Council Animal Care. Embryos obtained           zebrafish embryos incubated 50 &#206;&#188;l protease natural spawnings AB strain. Developmental            solution (2 units/ml collagenase (Roche) 60 units/ml <br /> stages reported hours post-fertilization (hpf) 28&#194;&#176;C.   dispase (Roche) DMEM 2 h 37&#194;&#176;C. Cells   NCI-H2009 tumor cells, transfected siRNA          gently dispersed pipetting dissociate transplanted <br /> ACK1, SRC, negative control, cultured 37&#194;&#176;C       embryo single cell suspension. 50 &#206;&#188;l 8% parafor- 80% confluency, detached using Trypsin-EDTA solution          maldehyde solution added directly wells fix <br /> (Sigma), washed twice DPBS (Gibco, Invitrogen)          count fluorescent cells. incubated 20 min 37&#194;&#176;C serum free culture <br /> media containing 0.05% DiD (Vibrant, Invitrogen).       Clinical data <br /> incubation 20 min, cells washed twice        Cases resected lung adenocarcinoma 10 years <br /> incubated 5 h media containing 0.25 &#206;&#188;M bosutinib.         period retrieved lung cancer database <br /> Cells washed twice suspended DPBS          maintained National Cancer Centre Singapore. Clinical <br /> jection. 24&#226;&#8364;&#8220;30 hpf zebrafish embryos dechorionated          outcome data including overall relapse-free survival anesthetized tricaine (Sigma). Using Nanoject II        collected database. retrospective  <br /> (Drummond) injector, 200 cells injected yolk       come data approved Singhealth ethics review embryo. injection, embryos incubated          committee. 2 h 31&#194;&#176;C checked successful injection. Em- <br /> bryos fluorescent cells outside yolk sack          Construction tissue microarray (TMA) <br /> excluded experimentation analysis.              Paraffin embedded formalin fixed tissue blocks paired <br /> Injected embryos transferred 96 plate             slides retrieved reviewed, representative <br />  embryo  containing Bosutinib (0.25 &#206;&#188;M) diluted         tumor areas selected TMA construction. Selected 200 ml E3 media  methylene blue)          tumor samples punched tissue blocks using <br /> incubated 35&#194;&#176;C 46 h. Control embryos drug         Beecher microarrayer. Briefly, sample treated incubated diluent (DMSO).                morphologically non-tumor area adjacent tumour <br />                                                                  morphologically representative tumor areas Quantification cellular migration metastasis              defined based haematoxylin eosin  -stained zebrafish                                                     sections. areas, tissue cylinder Cellular migration metastasis xenotransplanted            punched blocks transferred recipi- <br /> tumor cells zebrafish embryos greatly influenced        ent paraffin block. cylinder diameter 2.0 mm. number cells injected, cell survival drug <br /> treatment, time incubation post injection.        Immunohistochemistry <br /> consistent quantitative comparison cellular migration         4 mm sections cut TMA blocks fished different tumor cell lines different drug treat-     coated slides (POLYSINE, Menzel-glaser) similar <br /> ments, Migration Index calculated analysis         orientation facilitate evaluation. Sections stained <br /> performed microscopic imaging. Embryos               anti-ACK1 antibody using optimized protocols. Briefly, <br /> anesthetized microscope slide 48 h post injection        paraffin sections formalin-fixed tissue stained  Tan et al. Molecular Cancer 2014, 13:13                                                                                                                  Page 9 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> ACK1 using anti-ACK (sc-323 Santa Cruz Biotechnology)                                  Additional file 4: Figure S3. Bosutinib inhibition cell migration 1:100 dilution. Sections pretreated citrate                               AXL independent.   50 &#206;&#188;g lysate protein analyzed total AXL protein <br /> buffer (pH 6.0) 110&#194;&#176;C 15 minutes pressure                                using Western blot. 500 &#206;&#188;g individual lysate immunoprecipitated <br />                                                                                        anti-AXL (AF154) immunoblot antiphosphotyrosine (4G10). <br /> cooker. staining Dako Autostainer plus                               PVDF membrane stripped blotted anti-AXL (C-20). <br /> (Dako Colorado, , USA) fully automated immuno-                                (B) NCI-H1792 transfected siRNA using Oligofectamine 72 h. <br /> histochemical staining visualization Dako REAL&#226;&#8222;&#162;                                 serum starved cells trysinized seeded upper chamber <br />                                                                                        Transwell (8 &#206;&#188;m pore), presence DMSO bosutinib EnVision&#226;&#8222;&#162; Detection (K5007). breast cancer                                    various concentrations. Medium containing 10% FBS DMSO bosutinib <br /> section used positive control according antibody                             used chemoattractant lower chamber. Cells fixed data sheet.                                                                            stained 0.5% crystal violet blue 6 h. Cells migrated                                                                                        filter counted. Experiments carried duplicates    Stained slides scanned using ScanScope digital                                 random fields counted. Knockdown confirmed western blot analysis <br /> scanners (Aperio, Vista, CA). Scanned slides                                 50 &#206;&#188;g total protein right. <br /> viewed scored using Aperio Image Scope deter- intensity immunostaining. ACK1 immunopositiv-                              Abbreviations <br /> ity defined presence brown cytoplasmic staining.                         ACK1: Activated Cdc42 associated kinase 1; UBA: Ubiquitin association <br /> Staining intensity scored 0, 1+, 2+ 3+   weak,                       domain; EGFR: Epidermal growth factor receptor; RCC: Renal clear cell <br />                                                                                    carcinoma; EMT: Epithelial-mesenchymal transition; TNF: Tumor necrosis <br /> moderate strong staining, respectively). Percentage                         factor; HSP60: Heat shock protein 60. <br /> positively stained tumor cells assessed proportion total number tumor cells present section.                          Competing interests <br /> tensity percentage score (IP) documented. Intensity                           authors declare conflict  <br /> percentage score defined product maximum <br /> immunostaining intensity percentage tumor cells                             Authors&apos; contributions <br /> stained. Staining scored independently certi-                          DSW provided managed clinical samples. BH performed                                                                                    statistical analysis. JMT SCT did cell-based experiments. fied pathologists (Dr Lim KH Dr Takano .                                     HPL set zebrafish metastasis assay analysed data. SSK                                                                                    MMMT performed histological sectioning IHC staining                                                                                    HKL provided professional pathological assessment staining. EHT Statistical analysis                                                               WTL provided clinical input advises. work performed <br />                                                                                    support AU EHT. manuscript drafted DSW Tumor non-tumor ACK1 immunohistochemistry                                      BTC. authors read approved final manuscript. <br /> measures compared using paired t-tests. Overall relapse-free survival compared context                             Acknowledgements Cox proportional hazards models, individually                              work supported Biomedical Research council (BMRC) Agency adjusting important covariates stage                         Science Technology Research (ASTAR) National Cancer Centre <br />                                                                                    Singapore. work funded National Medical Research <br /> grade. Analysis performed R statistical software.                           Council Grant (NMRC/1224/2009), National Cancer Centre Research Fund <br /> Data preclinical experiments analysed                                (NRFMP10111-10112). grateful Trailblazer Foundation  <br /> presented using Graphpad Prism version 6.0c.                                       instrumental support Lung Cancer Consortium Singapore <br />                                                                                    (NRFTB11122). <br />  <br />                                                                                    Author details <br /> Additional files                                                                   1 <br />                                                                                     Department Medical Oncology, National Cancer Centre Singapore, <br />                                                                                    Singapore, Singapore. 2Cancer Therapeutics Research Laboratory, National <br />  Additional file 1: Figure S1. Bosutinib inhibit cell migration                Cancer Centre Singapore, Singapore, Singapore. 3Centre Quantitative <br />  invasion ACK1 dependent SRC independent. SK-Lu-1                      Medicine, Office Clinical Sciences, Duke-NUS Graduate Medical School, <br />  transfected various siRNA using Oligofectamines harvested                Singapore, Singapore. 4Department Statistics Applied Probability, <br />  72 h.   Quantitative real time PCR analysis performed using              National University Singapore, Singapore, Singapore. 5Singapore <br />  20 ng cDNA respective primer set ack1 src normalized               OncoGenome Laboratory, Institute Medical Biology, Agency Science <br />  gapdh. serum-starved cells trysinized seeded                  Technology Research, Singapore, Singapore. 6Biomedcore , 1580 <br />  upper chamber Transwells (8 &#206;&#188;m pore, B) MatrixgelTM(C),              Rossi Drive, Tecumseh N9A 6 J3, Canada. 7Department Pathology, <br />  presence DMSO 0.5 &#206;&#188;M bosutinib. Medium containing                    Singapore General Hospital, Singapore, Singapore. 8p53 Laboratory, <br />  10% FBS DMSO bosutinib (0.5 &#206;&#188;M) used chemoattractant             Biomedical Science Institutes Agency Science Technology Research, <br />  lower chamber. Cells fixed stained 0.5% crystal violet blue     Singapore, Singapore. 9Max-Planck Institute Biochemistry, Klopferspitz, <br />  6 h (migration, B) 24 h (invasion, C). Cells migrated   Martinsried, Germany. 10INM-SOG, Institute Molecular Cell Biology, <br />  filter counted. Experiments carried duplicates         Agency Science Technology Research, Singapore, Singapore. <br />  random fields counted. <br />                                                                                    Received: 24 September 2013 Accepted: 21 January 2014 <br />  Additional file 2: FigureS2. Real time PCR analysis ACK1 SRC.               Published: 24 January 2014 <br />  NCI-H2009 transfected siRNA (control, ACK1 SRC) using <br />  Oligofectamine 72 h. cells harvested 72 h. Quantitative <br />  real-time PCR analysis performed using 20 ng cDNA respective           References <br />  primers set ack1 src normalized gapdh.                             1. Jemal  Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer <br />  Additional file 3: Table S1. Individual relationships OS RFS               statistics. CA Cancer J Clin 2011, 61:69&#226;&#8364;&#8220;90. <br />                                                                                    2. Li T, Kung H-J, Mack PC, Gandara DR: Genotyping genomic profiling <br />  clinical variables ACK1 measures tumor paired <br />  non-tumor tissues.                                                                    non-small-cell lung cancer: implications current future therapies. <br />                                                                                        J Clin Oncol 2013, 31:1039&#226;&#8364;&#8220;1049. <br />  Tan et al. Molecular Cancer 2014, 13:13                                                                                                                   Page 10 10 <br /> http://www.molecular-cancer.com/content/13/1/13 <br />  <br />  <br />  <br />  <br /> 3.    Tan DSW, Gerlinger M, Teh BT, Swanton C: Anti-cancer drug resistance:           23. Liu  Adams HC, Whitehead IP: rho-specific <span id='am-37' about='obo:IMR_0200319' typeof='owl:Thing obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001998'><span id='am-38' property="oboInOwl:hasDbXref" content="KEGG:C00242" datatype="xsd:string"></span><span id='am-39' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-40' property="oboInOwl:id" content="IMR:0200319" datatype="xsd:string"></span><span id='am-41' property="rdfs:label" content="Guanine" datatype="xsd:string"></span>guanine</span> <span id='am-29' about='obo:IMR_0001349' typeof='owl:Thing obo:IMR_0001657 obo:IMR_0000947 obo:IMR_0000001 obo:IMR_0001698'><span id='am-30' property="oboInOwl:hasDbXref" content="CHEBI:25608" datatype="xsd:string"></span><span id='am-31' property="oboInOwl:hasExactSynonym" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-32' property="rdfs:label" content="nucleotide" datatype="xsd:string"></span><span id='am-33' property="oboInOwl:hasOBONamespace" content="molecule_role" datatype="xsd:string"></span><span id='am-34' property="oboInOwl:id" content="IMR:0001349" datatype="xsd:string"></span><span id='am-35' property="rdfs:label" content="nucleoside phosphate" datatype="xsd:string"></span><span id='am-36' property="obo:IAO_0000115" content="A nucleotide consists of a nitrogen-containing base, a five-carbon sugar, and one or more phosphate groups. Nucleotides can carry chemical energy (e.g. ATP), form coenzymes (e.g. CoA), be used as specific signaling molecules (e.g. cAMP) in the cell. Nucleotides are the subunits of the nucleic acids. " datatype="xsd:string"></span>nucleotide</span> <br />       understanding mechanisms use integrative genomics                exchange factor Dbs regulates breast cancer cell migration. J Biol Chem <br />       functional RNA interference. Eur J Cancer 2010, 46:2166&#226;&#8364;&#8220;2177.                   2009, 284:15771&#226;&#8364;&#8220;15780. <br /> 4.    Manser E, Leung T, Salihuddin H, Tan L, Lim L: non-receptor tyrosine          24. Pao-Chun L, Chan PM, Chan W, Manser E: Cytoplasmic ACK1 interaction <br />       kinase inhibits GTPase activity p21cdc42. Nature 1993,                  multiple receptor tyrosine kinases mediated Grb2: analysis <br />       363:364&#226;&#8364;&#8220;367.                                                                        ACK1 effects Axl signaling. J Biol Chem 2009, 284:34954&#226;&#8364;&#8220;34963. <br /> 5.    Kato-Stankiewicz J, Ueda S, Kataoka T, Kaziro Y, Satoh T: Epidermal growth      25. Konantz M, Balci TB, Hartwig UF, Dellaire G, Andr&#195;&#169; MC, Berman JN, Lengerke <br />       factor stimulation ACK1/Dbl pathway Cdc42 Grb2-dependent            C: Zebrafish xenografts tool vivo studies human cancer. <br />       manner. Biochem Biophys Res Commun 2001, 284:470&#226;&#8364;&#8220;477.                               Ann N Y Acad Sci 2012, 1266:124&#226;&#8364;&#8220;137. <br /> 6.    Teo M, Tan L, Lim L, Manser E: tyrosine kinase ACK1 associates         26. Roberts PJ, Stinchcombe TE: KRAS Mutation: Test        clathrin-coated vesicles binding motif shared arrestin             Does Matter? J Clin Oncol 2013, 31:1112&#226;&#8364;&#8220;1121. <br />       adaptors. J Biol Chem 2001, 276:18392&#226;&#8364;&#8220;18398.                              27. Zhang Y-X, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, Szabadkai  <br /> 7.    Shen F, Lin Q, Gu Y, Childress C, Yang W: Activated Cdc42-associated                Daub H, K&#195;&#169;ri G, Ullrich  AXL potential target therapeutic intervention <br />       kinase 1 component EGF receptor signaling complex regulates             breast cancer progression. Cancer Res 2008, 68:1905&#226;&#8364;&#8220;1915. <br />       EGF receptor degradation.  <br /> </body></html>